Literature DB >> 17055326

Assessing health-related quality of life in patients with Parkinson's disease in a prospective longitudinal study.

M Reuther1, E A Spottke, J Klotsche, O Riedel, H Peter, K Berger, O Athen, R Köhne-Volland, R C Dodel.   

Abstract

OBJECTIVE: To prospectively assess the health-related quality of life (HrQoL) in Parkinson's disease (PD) during 12 months.
METHODS: HrQoL was assessed in 145 PD patients using the PD-specific PDQ-39, PDQL and the generic EQ-5D. In addition, clinical rating-scales were used.
RESULTS: All scales showed a pronounced effect of PD. In comparison to an age-matched population the EQ-5D was considerably affected. In comparison to baseline, however, there was no significant change in the generic scale but a significant change in the sum-score of disease-specific HrQoL-scales.
CONCLUSIONS: Only disease-specific scales were sensitive to change. Further studies are necessary to evaluate the time-dependent change in HrQoL.

Entities:  

Mesh:

Year:  2006        PMID: 17055326     DOI: 10.1016/j.parkreldis.2006.07.009

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  28 in total

1.  Health-related quality of life of australians with Parkinson disease: a comparison with international studies.

Authors:  Sze-Ee Soh; Jennifer L McGinley; Jennifer J Watts; Robert Iansek; Meg E Morris
Journal:  Physiother Can       Date:  2012       Impact factor: 1.037

2.  The impact of motor and non motor symptoms on health state values in newly diagnosed idiopathic Parkinson's disease.

Authors:  James Shearer; Colin Green; Carl E Counsell; John P Zajicek
Journal:  J Neurol       Date:  2011-08-05       Impact factor: 4.849

3.  Individualization of levodopa treatment using a microtablet dispenser and ambulatory accelerometry.

Authors:  Dongni Johansson; Anders Ericsson; Anders Johansson; Alexander Medvedev; Dag Nyholm; Fredrik Ohlsson; Marina Senek; Jack Spira; Ilias Thomas; Jerker Westin; Filip Bergquist
Journal:  CNS Neurosci Ther       Date:  2018-01-25       Impact factor: 5.243

Review 4.  Cost effectiveness of pharmacotherapies in early Parkinson's disease.

Authors:  Karla M Eggert; Jens P Reese; Wolfgang H Oertel; Richard Dodel
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

5.  Health economic burden of patients with restless legs syndrome in a German ambulatory setting.

Authors:  Richard Dodel; Svenja Happe; Ines Peglau; Geert Mayer; Jürgen Wasem; Jens-Peter Reese; Guido Giani; Max Geraedts; Claudia Trenkwalder; Wolfgang H Oertel; Karin Stiasny-Kolster
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

6.  Responsiveness of the EQ-5D and 8-item Parkinson's Disease Questionnaire (PDQ-8) in a 4-year follow-up study.

Authors:  Nan Luo; Wai-Yee Ng; Puay-Ngoh Lau; Wing-Lok Au; Louis Cs Tan
Journal:  Qual Life Res       Date:  2010-03-04       Impact factor: 4.147

7.  Turkish Version Study of "Parkinson's Disease Quality of Life Questionnaire" (PDQL).

Authors:  Elif Elçin Dereli; Ayşe Yaliman; Tuğba Kuru Çolaka; Aycan Çakmak; Arzu Razak Özdinçler; Şule Badilli Demirbaş
Journal:  Noro Psikiyatr Ars       Date:  2015-06-01       Impact factor: 1.339

8.  Impact of community pharmaceutical care on patient health and quality of drug treatment in Parkinson's disease.

Authors:  Sabrina Schröder; Peter Martus; Per Odin; Marion Schaefer
Journal:  Int J Clin Pharm       Date:  2012-07-19

9.  Health-related quality of life in Parkinson disease: correlation between Health Utilities Index III and Unified Parkinson's Disease Rating Scale (UPDRS) in U.S. male veterans.

Authors:  Galit Kleiner-Fisman; Matthew B Stern; David N Fisman
Journal:  Health Qual Life Outcomes       Date:  2010-08-30       Impact factor: 3.186

10.  Social and clinical determinants of quality of life in Parkinson's disease in Austria: a cohort study.

Authors:  Yaroslav Winter; Sonja von Campenhausen; Julia Gasser; Klaus Seppi; Jens-P Reese; Karl-P Pfeiffer; Kai Bötzel; Wolfgang H Oertel; Richard Dodel; Werner Poewe
Journal:  J Neurol       Date:  2009-11-28       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.